{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:02:22Z","timestamp":1785787342645,"version":"3.56.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since its establishment in 1962, the Vaccine and Treatment Evaluation Units (VTEUs) have employed cutting-edge technologies to develop novel vaccines and therapeutics to mitigate emerging public health threats in the United States and globally. Clinical trial innovation has been the hallmark of these efforts as novel approaches to testing countermeasures are investigated in pace with advances in technology and evolving public health needs. The spectrum of trials conducted by the VTEUs ranges from proof-of-concept or first-in-human phase 1 to late-phase trials that establish efficacy and inform licensure decisions or \u201creal world\u201d vaccine usage such as with the coronavirus disease 2019 (COVID-19) and rotavirus mix-and-match trials aimed to inform standard of care. The VTEUs have also been instrumental in developing experimental wild-type challenge studies to preliminarily assess vaccine immunogenicity against influenza, shigellosis, cholera, enterotoxigenic Escherichia coli, enteropathogenic E. coli, and malaria to help select promising vaccine candidates for further development. During the COVID-19 pandemic, novel strategies for recruitment and improved accessibility of vaccine clinical trials emerged. However, the pandemic also highlighted the need for improved representation in clinical trials and underscored the importance of community engagement. As we consider what challenges to address in the upcoming years, engagement of the population in clinical trials is critical to establishing safety and efficacy and community acceptance of vaccines and therapeutics. It is imperative to develop skills that engender community advocacy while staying on the cutting edge of science, henceforth serving as the guideposts for new frontiers in clinical trial innovation.<\/jats:p>","DOI":"10.1093\/cid\/ciaf377","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:21:51Z","timestamp":1760113311000},"page":"S117-S124","source":"Crossref","is-referenced-by-count":2,"title":["Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8084-6941","authenticated-orcid":false,"given":"Kathryn","family":"Jano","sequence":"first","affiliation":[{"name":"NYU Langone Vaccine Center, New York University Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-4077","authenticated-orcid":false,"given":"Tara M","family":"Babu","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-1666","authenticated-orcid":false,"given":"Angelica C","family":"Kottkamp","sequence":"additional","affiliation":[{"name":"NYU Langone Vaccine Center, New York University Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina A","family":"Rebolledo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Parameswaran","sequence":"additional","affiliation":[{"name":"NYU Langone Vaccine Center, New York University Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-3709","authenticated-orcid":false,"given":"Zanthia","family":"Wiley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-5352","authenticated-orcid":false,"given":"Angela R","family":"Branche","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-6431","authenticated-orcid":false,"given":"Karen","family":"Kotloff","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025101012214956200_ciaf377-B1","author":"National Institute of Allergy and Infectious Diseases"},{"key":"2025101012214956200_ciaf377-B2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","article-title":"Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial","volume":"10","author":"Wolfe","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025101012214956200_ciaf377-B5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"key":"2025101012214956200_ciaf377-B6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199805143382002","article-title":"The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children","volume":"338","author":"Belshe","year":"1998","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.vaccine.2020.12.023","article-title":"Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing","volume":"39","author":"Friedman-Klabanoff","year":"2021","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B8","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiae062","article-title":"Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with glucopyranosyl lipid A-liposome Quillaja saponaria 21: results of phase 1 testing with malaria challenge","volume":"229","author":"Friedman-Klabanoff","year":"2024","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1086\/315871","article-title":"Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes","volume":"182","author":"Nardin","year":"2000","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B10","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1128\/IAI.67.12.6341-6345.1999","article-title":"Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination","volume":"67","author":"Tacket","year":"1999","journal-title":"Infect Immun"},{"key":"2025101012214956200_ciaf377-B11","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2016.09.041","article-title":"A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation","volume":"34","author":"Spearman","year":"2016","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/infdis\/173.1.44","article-title":"Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center","volume":"173","author":"Clements","year":"1996","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.vaccine.2017.02.032","article-title":"Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial","volume":"35","author":"Jackson","year":"2017","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B14","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B16","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1002\/cti2.1239","article-title":"Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation","volume":"10","author":"Salerno-Goncalves","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"2025101012214956200_ciaf377-B17","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1016\/j.vaccine.2017.07.024","article-title":"Tularemia vaccine: safety, reactogenicity, \u201ctake\u201d skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain\u2014a phase 2 randomized clinical trial","volume":"35","author":"Mulligan","year":"2017","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"key":"2025101012214956200_ciaf377-B19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/infdis\/jir837","article-title":"Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial","volume":"205","author":"El Sahly","year":"2012","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jis427","article-title":"Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons","volume":"206","author":"Jackson","year":"2012","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/infdis\/163.5.1023","article-title":"The A\/Mallard\/6750\/78 avian-human, but not the A\/Ann Arbor\/6\/60 cold-adapted, influenza A\/Kawasaki\/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children","volume":"163","author":"Steinhoff","year":"1991","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B22","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1016\/j.vaccine.2012.04.044","article-title":"Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009","volume":"30","author":"Chen","year":"2012","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B23","doi-asserted-by":"crossref","first-page":"e12874","DOI":"10.1111\/tid.12874","article-title":"A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation","volume":"20","author":"Miller","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2025101012214956200_ciaf377-B24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cid\/ciae192","article-title":"COVID-19 vaccine efficacy in participants with weakened immune systems from 4 randomized controlled trials","volume":"79","author":"Sherman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025101012214956200_ciaf377-B25","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1016\/j.vaccine.2023.06.066","article-title":"Modifiers of COVID-19 vaccine efficacy: results from four COVID-19 prevention network efficacy trials","volume":"41","author":"Turley","year":"2023","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B26","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","article-title":"Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia","volume":"388","author":"Haidara","year":"2023","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciae173","article-title":"A phase 2 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of different prime-boost vaccination schedules of 2013 and 2017 A(H7N9) inactivated influenza virus vaccines administered with and without AS03 adjuvant in healthy US adults","volume":"78","author":"Rostad","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025101012214956200_ciaf377-B28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"2025101012214956200_ciaf377-B29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/iai.26.1.274-279.1979","article-title":"Live Victoria\/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus","volume":"26","author":"Douglas","year":"1979","journal-title":"Infect Immun"},{"key":"2025101012214956200_ciaf377-B30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0264-410X(99)00334-5","article-title":"Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses","volume":"18","author":"Treanor","year":"1999","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B31","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","article-title":"Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin\u2013deleted Shigella dysenteriae type 1 strain","volume":"164","author":"Samandari","year":"2000","journal-title":"J Immunol"},{"key":"2025101012214956200_ciaf377-B32","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2018.06.063","article-title":"A phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei","volume":"36","author":"Frenck","year":"2018","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/21645515.2019.1578922","article-title":"A roadmap for enterotoxigenic Escherichia coli vaccine development based on volunteer challenge studies","volume":"15","author":"Levine","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2025101012214956200_ciaf377-B34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/IAI.66.1.52-58.1998","article-title":"Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge","volume":"66","author":"Donnenberg","year":"1998","journal-title":"Infect Immun"},{"key":"2025101012214956200_ciaf377-B35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/328257a0","article-title":"Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites","volume":"328","author":"Herrington","year":"1987","journal-title":"Nature"},{"key":"2025101012214956200_ciaf377-B36","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1172\/JCI116717","article-title":"Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection","volume":"92","author":"Donnenberg","year":"1993","journal-title":"J Clin Invest"},{"key":"2025101012214956200_ciaf377-B37","doi-asserted-by":"crossref","first-page":"e20152603","DOI":"10.1542\/peds.2015-2603","article-title":"Safety and immunogenicity of sequential rotavirus vaccine schedules","volume":"137","author":"Libster","year":"2016","journal-title":"Pediatrics"},{"key":"2025101012214956200_ciaf377-B38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.vaccine.2017.12.042","article-title":"Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals","volume":"36","author":"Widdice","year":"2018","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1542\/peds.96.3.548","article-title":"Comparison of 13 acellular pertussis vaccines: overview and serologic response","volume":"96","author":"Edwards","year":"1995","journal-title":"Pediatrics"},{"key":"2025101012214956200_ciaf377-B40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025101012214956200_ciaf377-B41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B42","doi-asserted-by":"crossref","first-page":"e2251974","DOI":"10.1001\/jamanetworkopen.2022.51974","article-title":"Rapid development of an integrated network infrastructure to conduct phase 3 COVID-19 vaccine trials","volume":"6","author":"Mena Lora","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025101012214956200_ciaf377-B43","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat Med"},{"key":"2025101012214956200_ciaf377-B44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac982","article-title":"Safety and immunogenicity of influenza A\/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses","author":"Neuzil","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025101012214956200_ciaf377-B45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.vaccine.2017.12.061","article-title":"Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74\u202fyears of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"2025101012214956200_ciaf377-B46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/infdis\/jiad441","article-title":"Phase 1 open-label dose escalation trial for the development of a human bacillus Calmette-Guerin challenge model for assessment of tuberculosis immunity in vivo","volume":"229","author":"Blazevic","year":"2024","journal-title":"J Infect Dis"},{"key":"2025101012214956200_ciaf377-B47","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199011153232006","article-title":"Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group","volume":"323","author":"Ward","year":"1990","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B48","doi-asserted-by":"crossref","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025101012214956200_ciaf377-B49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012214956200_ciaf377-B50","doi-asserted-by":"crossref","first-page":"100984","DOI":"10.1016\/j.lanmic.2024.100984","article-title":"Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial","volume":"6","author":"Deming","year":"2025","journal-title":"Lancet Microbe"},{"key":"2025101012214956200_ciaf377-B51","doi-asserted-by":"crossref","first-page":"e2023064252","DOI":"10.1542\/peds.2023-064252","article-title":"Maternal COVID-19 vaccination and prevention of symptomatic infection in infants","volume":"153","author":"Cardemil","year":"2024","journal-title":"Pediatrics"},{"key":"2025101012214956200_ciaf377-B52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s13063-024-08471-5","article-title":"Recommendations for developing accessible patient information leaflets for clinical trials to address English language literacy as a barrier to research participation","volume":"25","author":"Wylde","year":"2024","journal-title":"Trials"},{"key":"2025101012214956200_ciaf377-B53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11606-024-09162-2","article-title":"Navigating the path to inclusion: understanding barriers and facilitators to clinical trial participation among Chinese older adults in the United States with multimorbidity","volume":"40","author":"Tarn","year":"2024","journal-title":"J Gen Intern Med"},{"key":"2025101012214956200_ciaf377-B54","doi-asserted-by":"crossref","first-page":"e31321","DOI":"10.1002\/pbc.31321","article-title":"Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: a qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group","volume":"71","author":"Santacroce","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"2025101012214956200_ciaf377-B55","volume-title":"Improving representation in clinical trials and research: building research equity for women and underrepresented groups","author":"National Academies of Sciences, Engineering, and Medicine","year":"2022"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_2\/S117\/64613690\/ciaf377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_2\/S117\/64613690\/ciaf377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:21:56Z","timestamp":1760113316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/Supplement_2\/S117\/8280517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":55,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf377","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,10,10]]}}}